Effects of Mogroside Intervention on the Levels of Delayed-Onset Muscle Soreness-Related Indicators
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 16
- 主要终点
- Muscle Soreness Assessed by Visual Analog Scale (VAS)
研究概览
简要总结
This study will examine whether taking mogrosides, natural compounds found in monk fruit, affects delayed-onset muscle soreness (DOMS) and related markers of muscle damage, inflammation, oxidative stress, and muscle function after strenuous exercise. The study will also explore whether changes in the body's antioxidant capacity are related to changes in DOMS-related measures.
The study plans to enroll 16 healthy young male students. Participants will be randomly assigned to a control group (n=8) or an experimental group (n=8). The control group will receive a placebo, and the experimental group will receive mogrosides. Participants will take their assigned product by mouth for 27 days, perform a standardized frog-jump training session, and then continue taking the assigned product for 3 more days.
Researchers will measure subjective muscle soreness using a visual analog scale (VAS) at baseline before supplementation, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. At these same time points, they will also measure serum creatine kinase (CK) and creatine kinase isoenzyme MM (CK-MM) activity, total antioxidant capacity (T-AOC), malondialdehyde (MDA), plasma interleukin-6 (IL-6), thigh circumference at the junction of the middle and lower thirds of the thigh, maximal isometric strength for lifting the thigh, and active range of motion (AROM) of the knee.
The study will assess the effects of mogroside supplementation on DOMS severity and on changes in muscle damage, inflammation, oxidative stress, and muscle function. It will also explore whether improved antioxidant capacity is related to changes in DOMS-related indicators. This study is not yet recruiting participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 23 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male, aged 20 to 23 years.
- •Healthy, with no history of major diseases or severe injuries.
- •Physical fitness level comparable to that of an ordinary physical education/sports student.
- •No training or competition obligations during the study period.
- •Provides informed consent for the study protocol.
排除标准
- •History of musculoskeletal injury within the past 2 months.
- •Use of anti-inflammatory drugs or steroid medications within the past 1 month.
- •Use of antioxidant medications such as vitamin E or vitamin C within the past 1 month.
- •Use of any other medications within the past 2 weeks.
- •Participation in strenuous exercise within the past 10 days.
研究组 & 干预措施
Mogroside
Eight participants will be randomly assigned to the experimental arm. They will receive oral mogroside (batch no. YTC19011823; purity >95%; mogroside V 50.56%), prepared as a 3% (g/mL) solution in warm drinking water, at 6 g per dose twice daily (12 g/day) in the morning and evening for 27 days. After 27 days, participants will perform a standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same mogroside intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.
干预措施: Mogroside (Drug)
Placebo
Eight participants will be randomly assigned to the control arm. They will receive an equal volume of warm drinking water as placebo twice daily in the morning and evening for 27 days. After 27 days, participants will perform the same standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same placebo intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.
干预措施: Placebo (Other)
结局指标
主要结局
Muscle Soreness Assessed by Visual Analog Scale (VAS)
时间窗: From enrollment to the end of treatment at 30 days
Subjective muscle soreness will be assessed at six time points: before the first dose of study product, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. A 10-cm VAS ruler will be used. The side facing the participant is marked 0 at one end ("no pain") and 10 at the other ("worst imaginable pain"). Participants will move a cursor to indicate their current level of muscle soreness. The distance from the "no pain" end to the mark will be recorded as the pain score in centimeters. Higher scores indicate greater muscle soreness.
次要结局
- Active Range of Motion (AROM) of the Knee(From enrollment to the end of treatment at 30 days)
- Maximal Isometric Muscle Force for Lifting the Thigh(From enrollment to the end of treatment at 30 days)
- Thigh Circumference at the Junction of the Middle and Lower Thirds(From enrollment to the end of treatment at 30 days)
研究者
Jingzhi Zhang
Guangxi Normal University
Guangxi Normal University